The effect of sputum quality and volume on the yield of bacteriologically-confirmed TB by Xpert MTB/RIF and smear

Onani Zimba1, Tsaone Tamuhla2, Joyce Basoti1, Gaoraelwe Letsibogo2, Sherri Pais4, Unami Mathebula1, Anikie Mathoma1, Christopher Serumola1, Kitso Ramogale2, Rosanna Boyd1,5, Tiffany Tran1, Alyssa Finlay1,5, Andrew Auld4, Anand Date4, Heather Alexander4, Violet Chihota6,7, Tefera Agizew1,7,8,

1Centers for Disease Control and Prevention, Botswana, 2Botswana University of Pennsylvania, Botswana, 3National Tuberculosis Reference Laboratory, Ministry of Health and Wellness, Botswana, 4Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 5Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 6The Aurum Institute, Johannesburg, South Africa, 7School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa, 8Department of Family Medicine and Public Health, Faculty of Medicine, University of Botswana, Botswana

8Corresponding author: Tefera Agizew, Centers for Disease Control and Prevention, Department of Family Medicine and Public Health, Faculty of Medicine, University of Botswana, Botswana, School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa

Key words: Molecular diagnostic yield, sputum quality, Botswana

Received: 28/02/2018 - Accepted: 04/03/2019 - Published: 13/06/2019

Abstract

Introduction: the World Health Organization endorsed (2010) the use of Xpert MTB/RIF and countries are shifting from smear microscopy (smear)-based to Xpert MTB/RIF-based tuberculosis (TB) diagnostic algorithms. As with smear, sputum quality may predict the likelihood of obtaining a bacteriologically-confirmed TB when using Xpert MTB/RIF. Methods: from 08/12-11/2014, all people living with HIV were recruited at 22 clinics. For patients screened positive using the four TB symptoms their sputa were tested by Xpert MTB/RIF and smear. Laboratorians assessed and recorded sputum appearance and volume. The yield of bacteriologically-positive sputum evaluated using Xpert MTB/RIF and smear, likelihood-ratios were calculated. Results: among 6,041 patients enrolled 2,296 were presumptive TB, 1,305 (56.8%) had > 1 sputa collected and 644/1,305 (49.3%) had both Xpert MTB/RIF and smear results. Since >1 sputa collected from 644 patients 954 sputa were tested by Xpert MTB/RIF and smear. Bacteriologically-positive sputum was two-fold higher with Xpert MTB/RIF 11.4% versus smear 5.3%, p < 0.001. Sputum appearance and quantity were not predictive of bacteriologically-positive results, except volume of 2ml to < 3ml, tested by Xpert MTB/RIF LR+= 1.26 (95% CI, 1.05–1.50). Conclusion: Xpert MTB/RIF test yield to bacteriologically-positive sputum was superior to smear. Sputum quality and quantity, however, were not consistently predictive of bacteriologically-positive results by Xpert MTB/RIF or smear.

Pan African Medical Journal. 2019;33:110. doi:10.11604/pamj.2019.33.110.15319

This article is available online at: http://www.panafrican-med-journal.com/content/article/33/110/full/

© Onani Zimba et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

After endorsement by the World Health Organization (WHO) in 2010, over 145 countries implemented the Xpert MTB/RIF assay by 2016 [1]. With such an increased capacity many countries are shifting from a smear microscopy (smear)-to an Xpert MTB/RIF-based tuberculosis (TB) diagnostic algorithm. In 2011, the Botswana Ministry of Health and Wellness adopted WHO guidelines and incorporated Xpert MTB/RIF into the national TB diagnostic algorithm [2]. Optimal performance of Xpert MTB/RIF relies on the quality of the sputum samples submitted for testing [3]. The WHO quality control standard underscores collection of quality sputum, and salivary samples were considered suboptimal and thus prone to rejection by testing laboratories [4]. The minimum required raw sputum sample for smear is 3 - 5 ml [5] compared to 1ml for Xpert MTB/RIF per the Cepheid manufacturer (Cepheid, Sunnyvale, CA, USA) recommendation [6, 7]. Yoon et al. and Bhat et al. demonstrated that sputum gross appearance (quality) and volume (quantity) were associated with smear positivity [8, 9]. Similar to smear result, sputum quality and quantity may have an impact on the likelihood of obtaining a positive result when using Xpert MTB/RIF [3]. While national TB programs are expanding implementation of Xpert MTB/RIF [1], focus on collection of quality sputum with adequate volume has not been given priority [3]. Data on the effect of sputum quality and quantity on the yield of bacteriologically-confirmed TB using molecular tests such as Xpert MTB/RIF are scarce [3, 10]. We evaluated the proportion of bacteriologically-positive sputum samples with Mycobacterium tuberculosis (MTB) detected using Xpert MTB/RIF, compared to acid fast bacilli identified by smear, stratified by sputum quality and volume.

Methods

Study population

This is a sub-study of the Xpert MTB/RIF Package Rollout Evaluation Study using a stepped-wedge design (XPRES), registered at ClinicalTrials.gov, NCT02538952. Full details of the study protocol, including study populations, sample size, and procedures can be accessed in the published protocol [11]. XPRES enrolment began in 2012 as part of the Botswana’s national Xpert MTB/RIF rollout, together with intensified TB case finding (ICF) activities and strengthening HIV patient retention interventions at 22 HIV treatment clinics prior to phased implementation of 13 GeneXpert instruments.

Tuberculosis screening

At enrolment and each follow-up visit (i.e., at two weeks, then monthly for the first three months and then quarterly for the remaining follow up period), adults and adolescents (combined into one adult group and defined as persons >12 years) and children (0-12 years old) were screened for TB symptoms. Per protocol, adults were screened for four TB symptoms (cough, fever, night-sweats and weight-loss) of any duration. Children were screened for weight-loss or failure to thrive (no weight gain over 3 months, enlarged lymph nodes (more than 1 x 1 cm), ≥ 2 weeks of cough, fever, fatigue/reduced playfulness, and profuse night-sweats [2, 12].

Sputum collection, and assessment of macroscopic sputum quality

Patients who screened positive for any of these TB symptoms or signs were requested to provide four sputa; two were provided on the same day (Spot 1 and 2) and another two on the following day (Morning sputum collected at home and Spot 3 collected at the clinic). In the main study, XPRES, after GeneXpert instrument implementation each Spot 1 and 3 sputum specimen was tested by both Xpert MTB/RIF and smear at the peripheral laboratory. The focus of the sub-analysis was on patients who had at least one TB symptom and from whom at least one sputum was collected for both Xpert MTB/RIF and smear testing. Before GeneXpert instrument implementation each Spot 1 and 3 sputum specimen was tested only by smear at the peripheral laboratory as part of the main study. Spot 2 and morning sputum were submitted to the National TB Reference Laboratory for culture. The culture result was needed for sensitivity analysis of the XPRES study and thus not included in this analysis. Initially and throughout the study, study nurses received training on how to collect a high quality sputum. Training included the importance of: (1) collecting a mucoid rather than salivary sample, (2) collecting the sample in a private but well-ventilated area outside the clinic, (3) use of a sputum collection job aid to guide patients through sputum production, and (4) use of observation and assistance (e.g. patting the back of the patient) to assist as they attempt to produce sputum. Guidelines were also provided on sample storage and refrigeration while awaiting transport by cooler box to the peripheral laboratory. At the beginning of the study, laboratorians at peripheral labs received refresher training on how to classify gross appearance of sputum. Training materials included a visual job aid, a coloured poster illustrating the...
different possible sputum appearance types and standard classification. Upon receiving a sample, a laboratorian assessed the macroscopic appearance and volume of sputum samples by visualization and recorded results. Sputum appearance was graded into categories of salivary, mucoid, muco-purulent and blood-tinged or other. Sputum volume was measured in millilitres using a pre-calibrated sputum collection bottle as a reference. After grading the appearance and volume of the sputum, the sputum sample was placed in a refrigerator until the time for smear or Xpert MTB/RIF testing.

**Data collection**

Data were collected using standardized case report forms between August 2012 and November 2014. Data were double entered into a Clindex database (Fortress Medical Systems, Minneapolis, MN, USA). Inconsistencies and missing data were corrected through review of patient charts.

**Statistical analysis**

Data were analysed using STATA (StataCorp. 2015. *Stata Statistical Software: Release 14. College Station, TX: StataCorp LP*) to fit univariate and multiple logistic regression models; to describe and compare demographic and clinical characteristics of patients; and to compare patients with specimen specified sputum characteristic vs. those without that characteristic. All analyses were adjusted for within-clinic correlation. We fit generalized-linear-mixed-models with appearance characteristics coded as salivary vs. non-salivary, mucoid vs. non-mucoid, and muco-purulent vs non-muco-purulent to estimate likelihood ratios (LR+) for sputum quality characteristics and the diagnostic yield of *M. tuberculosis* testing and 95% confidence intervals. These models were first used to construct omnibus tests for all appearance indicators and all volume indicators for Xpert MTB/RIF and smear. If the omnibus test was significant, we proceeded to interpret the LR+ and confidence interval. If the omnibus test was not significant, we considered all pairwise comparisons non-significant. The models included a random effect for clinic to adjust for within-clinic correlation. LR+s were defined as: 1) Prevalence of a given sputum characteristic in Xpert MTB/RIF MTB-positive samples divided by the prevalence of the same sputum characteristic in Xpert MTB/RIF MTB negative samples; 2) Prevalence of a given sputum characteristic in AFB smear positive of sputum samples divided by the prevalence of the same sputum characteristic in smear negative samples. P values of < 0.05 were considered statistically significant.

**Ethical considerations**

The study protocol was approved by the Botswana Health Research and Development Committee, the Centers for Disease Control and Prevention, Atlanta, Georgia, Institutional Review Board (IRB), the University of Pennsylvania and the University of Witwatersrand, Johannesburg, South Africa IRB. Patients were enrolled following written informed consent process.

**Funding:** this research has been supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention.

**Disclaimer:** the findings and conclusions in this report are those of the authors and do not necessarily represent the official views of the funding agency and the Centers for Disease Control and Prevention. References in this manuscript to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation by the U.S. Government.

**Results**

Among 6,041 patients prospectively enrolled 2,296 (38.0%) screened positive for TB symptoms at enrolment or follow-up. Of these, 1305 (56.8%) patients submitted > 1 sputum sample and 991 (43.2%) did not have an available sputum sample for testing; of the 1305, 644 (49.3%) patients had both smear and Xpert MTB/RIF test results and 661 (50.7%) were only tested by either Xpert MTB/RIF or smear and not both (Figure 1). Combined 991 and 661, the 1,652 patients will be referred to as patients that "did not receive sputum testing by both Xpert MTB/RIF and smear". Table 1 summarized the demographic and clinical characteristics of patients (1,652) that did not receive sputum testing by both Xpert MTB/RIF and smear and those patients (644) tested by both methods. Overall, the two populations were similar in terms of age, gender, CD4 status, history of previous TB treatment and presenting symptoms. Patients who did not receive sputum testing by both Xpert MTB/RIF and smear presented less frequently with cough (45.8% vs. 62.3%, aOR 0.50, p < 0.001) and smoking (24.3% vs. 30.9%, aOR 0.67, p = 0.008) than those tested by both smear and Xpert MTB/RIF (Table 1).
Predictive value of sputum appearance and volume on bacteriologically-confirmed diagnostic yield

From 644 patients, 954 sputum samples were tested by both Xpert MTB/RIF and smear; 43.3% (413) were salivary, 14.4% (137) were mucoid, 40.5% (386) were muco-purulent, and 1.0% (10) were blood tinged. The diagnostic yield of MTB detected by Xpert MTB/RIF was more than two-fold higher than that of smear (11.4% vs. 5.3%), p < 0.001). For any category of sputum quality measures (gross appearance or volume), the diagnostic yield of bacteriologically-confirmed diagnostic yield was approximately two-fold higher when tested by Xpert MTB/RIF compared to smear (Table 2). Sputum appearance was not predictive of bacteriologically-positive sputum by either Xpert MTB/RIF or smear (Omnibus test p > 0.05). The omnibus test for sputum volume for Xpert MTB/RIF testing was significant (p < 0.05) and sputum volume of 2ml to < 3ml was predictive of a positive sputum Xpert MTB/RIF result, LR+=1.26 (95% CI: 1.05 – 1.50). On the other hand, sputum volume 1ml to < 2ml was less predictive of a positive Xpert MTB/RIF result, LR+=0.62 (95% CI: 0.44-0.87). The proportion of bacteriologically-confirmed diagnostic yield showed no improvement by either Xpert MTB/RIF or smear as sputum quality improved (Table 2).

Association between sputum appearance and TB diagnosis

Of 954 tested sputum samples, 43.3% were classified as salivary. The percentage of patients with salivary sputum ranged from 24-70% (Figure 2; Note: Athlon Hospital = ATH, Area W Clinic = AWC, Bobonong Primary Hospital = BOB, Bontleng Clinic = BON, Boseja Clinic = BOS, Botswelelo Clinic = BOT, Broadhurst Traditional Clinic = BTC, Deborah Retief Primary Hospital = DRM, Gantsi Primary Hospital = GAN, Letsholathebe II Memorial Hospital = LMH, Maun Clinic = MAU, Molepolole Council Clinic = MCC, Nkoyaphiri Clinic = NKO, Nyangabwe Referral Hospital = NRH Phuthadikobo Clinic = PHU, Seventh Day Adventist Hospital = SDA, Serowe Clinic = SER.) among study sites. Patient characteristics were similar among those who submitted salivary samples and non-salivary sputum samples (Table 3).

Discussion

Our study demonstrated that among PLHIV with TB symptoms attending HIV care and treatment services, Xpert MTB/RIF was superior to smear at confirming the presence of MTB in sputum as previously reported [13-15]. Sputum gross appearance and quantity, however, were not predictive of bacteriologically-positive sputum by Xpert MTB/RIF or smear suggesting that despite a minimum required volume of sputum - especially for Xpert MTB/RIF testing - suboptimal quality of sputum might have affect the yield of bacteriologically-confirmed TB [16, 17]. These findings are consistent with a previous report by Ho et al. [18] who analysed over 20,000 sputum samples collected as part of an active case finding project in Vietnam; they reported that the macroscopic quality was similarly not predictive of bacteriologically- positive sputum. In the present study the only exception was sputum volume of 2ml to < 3ml that was predictive for a positive result when tested by Xpert MTB/RIF.

The percentage of samples classified as salivary in the present study was high at 43.3%, indicating potentially that, despite the training administered, a high proportion of patients were only able to produce salivary specimens. Recent studies from Kenya and Uganda also reported on the proportion of salivary sputa. In Kenya 44% of the samples were salivary and the study showed that salivary sputa had lower diagnostic yield than mucoid sputa. In Uganda 4% of the samples were salivary and the study showed that salivary sputa had lower diagnostic yield than mucoid sputa using Xpert MTB/RIF testing [10]. The study in Uganda examined presumptive TB patients screened with > 2 weeks of cough; the proportion of salivary sputa was at 16% [19]. In both the Kenya and the Uganda studies the proportion of salivary sample was not affected by HIV status. In Uganda, Xpert MTB/RIF test was conducted only among smear negative patients, and the diagnostic sensitivity, in contrast to our findings and those from Kenya, was significantly higher on salivary samples than mucoid sputa [19]. The Uganda findings on salivary sputa seems contrary to biological plausibility, showing higher diagnostic yield with lower quality sputa. However, the report from Uganda was consistent after comparison of diagnostic accuracy in reference to mycobacterial culture (higher culture positive among salivary than non-salivary). Given the higher positivity among salivary sputum samples was confirmed by culture, we are in agreement with Meyer et al that further study is essential exploring the possibility of potential dynamics affecting the Xpert MTB/RIF amplification in salivary sputum [19]. Ho et al emphasized that assessment of sputum quality is a neglected aspect of accurate TB diagnostics [3]. Even though in the present study sputum quality was not predictive of diagnostic yield, we agree with Ho et al that TB programs should continue to train providers on high quality sputum collection techniques. It is worth noting that despite the high cost of rolling out, Xpert MTB/RIF implementation in the world is expanding [1]. Such investments and their ultimate impact will potentially be compromised if TB diagnostic algorithms do not
encompass collection of quality sputum [10]. A wide variability in the proportion of patients with salivary sample (24-70%) among clinics (Figure 2) suggest an inconsistency in sputum collection practices across the clinics. Bhat et al have shown an association of improved sputum quality and diagnostic yield [9]. It is time that TB screening and diagnostic algorithms include standardized methods of sputum collection and introduce a sputum collection system less prone to variability as suggested by Ho et al. [3].

In some previous reports, improving sputum quality increased TB diagnostic yield [18, 20-24]. Ho et al. were able to collect 99% mucoid or muco-purulent sputa by using sputum quality colour scale [18,20]; Alisjahbana et al., used instruction to patients, where patients were individually addressed on the importance of sputum examination and how to produce adequate samples; this technique demonstrated an improvement in sputum volume collection with thicker consistency and resulting in higher smear positivity rates [21]; Sicu et al. and Hirooka et al. using similar methods as Alisjahbana et al. showed higher quality and volume sputum samples that resulted in increased bacteriologically-confirmed TB diagnosis [22, 23]. Mhalu et al. demonstrated that sputum submission instructional videos increased the yield of TB cases through better quality of sputum samples [24]. In addition, training of health care workers and laboratorians on standardized methods of sputum collection and assessment of adequate quality sputum can improve sputum quality [9] and measuring a volume in millilitres using a graded reference container can facilitate appropriate volume collection [9]. With these various methods, achieving improved quality and quantity of sputum were possible but well-designed studies are still needed to define a more comprehensive approach and standard.

While endeavouring to standardize sputum collection methods, under current clinical and laboratory practices, at least five reasons stand out about why salivary sputum should not be rejected: (1) a high percentage of salivary sputum are still being collected in clinical practice by health workers [10]; (2) sputum specimen appearance and volume are poor “negative predictors” of MTB in sputum [8, 18]; (3) a limited volume (only 1ml) of non-concentrated sputum maybe acceptable for Xpert MTB/RIF testing [6, 7]; (4) recent study demonstrate higher sensitivity of Xpert MTB/RIF in salivary samples than mucoid [19] and (5) above all, to minimize any missed opportunities for TB diagnosis [25]. Sputum rejection criteria, that consider salivary sample as unsuitable for testing should be reconsidered, particularly when using Xpert MTB/RIF testing [3]. In the present study, if salivary samples had been rejected, 12% and 6% of TB cases identified by Xpert MTB/RIF and smear, respectively, would have been missed as bacteriologically-confirmed TB case. Our study has limitations. Not all patients with TB symptoms were able to provide sputum, and for those who were able to provide sputum some did not receive sputum testing by both Xpert MTB/RIF and smear or were not tested at all. However, the patient characteristics among those tested by both Xpert MTB/RIF and smear and not tested by both or at all were similar. We also did not assess nor document laboratorian skills in assessing the quality of sputa. Furthermore, there may have been inter and/or intra-operator variability in assessing sputum quality [26].

Conclusion

In conclusion, in the setting of HIV care and treatment, our study demonstrated that Xpert MTB/RIF was superior at confirming the presence of MTB in sputum samples from PLHIV at peripheral laboratories. However, sputum appearance and quantity were not consistently predictive for bacteriologically-confirmed positive sputum by Xpert MTB/RIF or smear. Despite a minimum required volume of sputum for Xpert MTB/RIF testing suboptimal quality of sputum have affected the yield of bacteriologically-confirmed TB. The high proportion of salivary samples warrants investigation and more effort should be made to re-train laboratorians and clinical staff in collecting good quality sputum and classifying sputum appearance in a standard manner.

What is known about this topic

- As with smear, sputum quality may predict the likelihood of obtaining a bacteriologically-confirmed TB when using Xpert MTB/RIF;
- Xpert MTB/RIF was superior to smear at confirming the presence of *Mycobacterium tuberculosis* in sputum.

What this study adds

- Due to poor quality (high proportion of salivary samples) sputum appearance and quantity were not consistently predictive for bacteriologically-confirmed positive sputum by Xpert MTB/RIF or smear;
- The need for re-train laboratorians and clinical staff in collecting good quality sputum;
Despite a minimum required volume of sputum for Xpert MTB/RIF testing suboptimal quality of sputum might have affected the yield of bacteriologically-confirmed TB.

Competing interests

The authors declare no competing interests.

Authors’ contributions

T.B., Z.O, T.T, A.A., A.M., U.M., A.D., H.A., J.B., S.C., V.C and R.B. designed the study. T.B., Z.O., T.T., R.K., L.G., A.M., U.M., B.J and A.F. conducted the field work. T.B., Z.O., A.F and S.P., conducted statistical analyses. All authors have read and agreed to the final version of this manuscript.

Acknowledgements

We thank the study participants, the clinic staff, the data entry team, and the research nurses and laboratorians who carried out the day-to-day work of the XPRES; the Botswana Ministry of Health healthcare workers for their generous cooperation.

Tables and figures

Table 1: characteristics of patients with presumptive tuberculosis (TB), by availability of sputum test results

Table 2: sputum characteristics from people living with HIV (PLHIV) with presumptive tuberculosis (TB)

Table 3: patient characteristics and quality of sputum

Figure 1: patients enrolled, screened for tuberculosis symptoms and tested by Xpert MTB/RIF and smear

Figure 2: proportion of salivary sputum by study sites

References

1. World Health Organization. Monitoring of Xpert MTB/RIF roll-out. Accessed on 21 July 2017.

2. National Tuberculosis Program Manual, Ministry of Health, Botswana 2011.

3. Ho J, Marks GB, Fox GJ. The impact of sputum quality on tuberculosis diagnosis: a systematic review. Int J Tuberc Lung Dis. 2015 May;19(5):537-44. PubMed | Google Scholar

4. World Health Organizations. Quality assurance of sputum microscopy in DOTS Programmes, 2003. Regional Office for the Western Pacific, ISBN 92 9061 056 5. Accessed on 21 July 2017.

5. Technical guide: sputum examination for tuberculosis by direct microscopy in low income countries. Fifth edition, Int Union of TB and Lung Dis, Paris, France. 2000.

6. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;(1):CD009593. PubMed | Google Scholar

7. Luetkemeyer AF, Finnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA et al. Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clin Infect Dis. 2016; 62(9): 1081-8. PubMed |Google Scholar

8. Yoon SH, Lee NK and Yim JJ. Impact of sputum gross appearance and volume on smear positivity of pulmonary tuberculosis: a prospective cohort study. BMC Infect Dis. 2012; 12: 172. PubMed | Google Scholar

9. Bhat J, Rao V, Muniyandi M. Impact of sputum quality and quantity on smear and culture positivity: findings from a tuberculosis prevalence study in central India. Trans R Soc Trop Med Hyg. 2014 Jan;108(1):55-6. PubMed | Google Scholar
10. Orina F, Mwangi M, Githui W, Ogaro T, Kiptoo M, Sang K et al. Effect of sputum quality on Xpert MTB/RIF® results in the detection of Mycobacterium tuberculosis from persons presumed to have Tuberculosis in EAPHLN project Operational Research study sites in Kenya. Jour of Afr Heal Scie. 2014;27(4):446-56. Google Scholar

11. Auld AF, Agizew T, Pals S, Finlay A, Ndwap N, Boyd R et al. Implementation of a pragmatic, stepped-wedge cluster randomized trial to evaluate impact of Botswana’s Xpert MTB/RIF diagnostic algorithm on TB diagnostic sensitivity and early antiretroviral therapy mortality. BioMed Central Infect Dis. 2016 Oct 26; 16(1):606. PubMed | Google Scholar

12. World Health Organization. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. © WHO. 2010. Google Scholar

13. Trajman A, Durovni B, Saraceni V, Menezes A, Cordeiro-Santos M, Cobelens F et al. Impact on patients’ treatment outcomes of Xpert MTB/RIF MTB/RIF implementation for the diagnosis of tuberculosis: follow-up of a stepped-Wedge Randomized Clinical Trial. PLoS One. 2015 Apr 27;10(4):e0123252. PubMed | Google Scholar

14. Churchyard G, Stevens W, Mametja L, McCarthy K, Chihota V, Nicol M et al. Xpert MTB/RIF versus sputum microscopy as an initial diagnostic test for tuberculosis: a cluster randomized trial embedded in South African roll out of Xpert MTB/RIF. Lancet Glob Health. 2015 Aug;3(8):e450-e457. PubMed | Google Scholar

15. Cox H, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemenay W et al. Impact of Xpert MTB/RIF for TB Dx in a PHC with high TB and HIV Prevalence in South Africa: a pragmatic randomized trial. PLoS Med. 2014 Nov 25;11(11):e1001760. PubMed | Google Scholar

16. Flæø A, Hilberg O, Thomsen VØ, Lillebaek T, Wejse C. Shortening isolation of patients with suspected tuberculosis by using polymerase chain reaction analysis: a nationwide cross-sectional Study. Clin Infect Dis. 2015 Nov 1;61(9):1365-73. PubMed | Google Scholar

17. Maurici-da-Silva R, Bazzo ML, Chagas M. Quality of sputum in the performance of polymerase chain reaction for sputum in the diagnosis of pulmonary tuberculosis. Brazilian. Journal of Infec Dis 2010; 14(1). Google Scholar

18. Ho J, Nguyen PTB, Nguyen TA. The role of macroscopic sputum quality assessments to optimize sputum testing for tuberculosis. Int J Tuberc Lung Dis. 2016 Mar;20(3):319-22. PubMed | Google Scholar

19. Meyer A, Atuhere C, Worodria W, Kizito S, Katamba A, Sanyu I et al. Sputum quality and diagnostic performance of GeneXpert among smear-negative adults with presumed tuberculosis in Uganda. PloS One. 2017 Jul 7;12(7):e0180572. PubMed | Google Scholar

20. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet. 2005 Apr 23-29;365(9469):1500-5. PubMed | Google Scholar

21. Alisjahbana B, van Crevel R, Danusantoso H, Gartinah T, Soemantri E, Neltan R et al. Better patient instruction for sputum sampling can improve microscopic tuberculosis diagnosis. Int J Tuberc Lung Dis. 2005 Jul;9(7):814-7. PubMed | Google Scholar

22. Sicsú AN, Salem JI, Fujimoto LB, Gonzales M, Cardoso Mdo S, Palha PF. Educational intervention for collecting sputum for tuberculosis: a quasi-experimental study. Rev Lat Am Enfermagem. 2016 Jun 7;24. pii: S0104-11692016000100333. PubMed | Google Scholar

23. Hirooka T, Higuchi T, Tanaka N, Ogura T. The value of proper sputum collection instruction in detection of acid-fast bacillus. Kekkaku. 2004 Feb;79(2):33-7. PubMed | Google Scholar

24. Mhalu G, Hella J, Doulla B. Do instructional videos on sputum submission result in increased tuberculosis case detection? a randomized controlled trial. PLoS One. 2015 Sep 29;10(9):e0138413. PubMed | Google Scholar

25. World Health Organization. Definitions and reporting framework for tuberculosis-2013 revision. Geneva, Switzerland: WHO, 2013 (updated December 2014). Accessed on 04 September 2016.
26. Albert H, Manabe Y, Lukyamuzi G, Ademun P, Makkada S, Nyesiga B et al. Performance of three LED-based fluorescence microscopy systems for detection of tuberculosis in Uganda. PLoS One. 2010 Dec 28;5(12):e15206. PubMed | Google Scholar

Table 1: characteristics of patients with presumptive TB, by availability of sputum test results

| Characteristics | Did not receive sputum testing by both Xpert and smear | Tested by both Xpert and smear | 95% CI** | p value |
|-----------------|------------------------------------------------------|--------------------------------|----------|---------|
| Age < 35        | 1652 723 43.8%                                      | 644 287 44.4%                  | 0.93     | 0.76-1.14 | 0.460  |
| Gender, female  | 1652 969 58.7%                                      | 644 368 57.1%                  | 0.95     | 0.67-1.33 | 0.752  |
| CD4 count < 200 | 1633 824 50.5%                                      | 636 317 49.8%                  | 0.94     | 0.71-1.23 | 0.628  |
| BMI < 18.5      | 1639 508 31.0%                                      | 644 171 26.6%                  | 1.32     | 0.96-1.82 | 0.086  |
| HbB < 10 mg/dl  | 1473 311 21.1%                                      | 564 116 20.6%                  | 1.02     | 0.80-1.30 | 0.895  |
| Previous TB     | 1649 237 14.4%                                      | 644 99 15.4%                   | 0.90     | 0.66-1.23 | 0.487  |
| Smoking***      | 1649 400 24.3%                                      | 644 199 30.9%                  | 0.67     | 0.50-0.89 | 0.008  |
| Alcohol use     | 1649 394 23.9%                                      | 644 170 26.4%                  | 1.11     | 0.77-1.62 | 0.552  |
| Miner           | 1649 114 6.9%                                       | 644 46 7.1%                    | 0.97     | 0.66-1.41 | 0.861  |
| Cough           | 1652 756 45.8%                                      | 644 401 62.3%                  | 0.50     | 0.36-0.70 | <0.001 |
| Fever           | 1652 380 23.0%                                      | 644 180 28.0%                  | 0.83     | 0.65-1.08 | 0.154  |
| Night-sweats    | 1652 392 23.7%                                      | 644 188 29.2%                  | 0.86     | 0.64-1.17 | 0.326  |
| Weight-loss      | 1652 955 57.8%                                      | 644 331 51.4%                  | 1.44     | 1.00-2.09 | 0.052  |

* AOR adjusted Odds Ratio
** CI: Confidence interval.
*** Current or ex-smoker

Table 2: sputum characteristics from PLHIV with presumptive TB

| Characteristics | n | Xpert MTB/RIF positive (%) | LR+ * (95% CI**) | Smear Positive (%) | LR+ (95% CI) |
|-----------------|---|----------------------------|------------------|-------------------|--------------|
| Gross appearance1 |   |                            |                  |                   |              |
| Salivary        | 413| 54 (13.1)                  | 1.17 (1.00-1.37)#| 27 (6.5)          | 1.24 (0.82-1.86) |
| Mucoid          | 137| 14 (10.2)                  | 0.88 (0.56-1.38) | 5 (3.7)           | 0.67 (0.27-1.70) |
| Mucopurulent    | 386| 38 (9.8)                   | 0.85 (0.67-1.06) | 19 (4.9)          | 0.92 (0.62-1.36) |
| Blood-tinged    | 10 | 0 (0.0)                    | n/a              | 0 (0.0)           | n/a          |
| Other           | 8  | 3 (37.5)                   | n/a              | 0 (0.0)           | n/a          |
| Volume2 |   |                            |                  |                   |              |
| <1ml            | 2  | 0 (0.0)                    | n/a              | 0 (0.0)           | n/a          |
| 1ml to < 2ml    | 272| 20 (7.4)                   | 0.62 (0.44-0.87) | 7 (2.3)           | 0.47 (0.22-1.01) |
| 2 ml to < 3ml   | 330| 40 (13.9)                  | 1.26 (1.05-1.50) | 25 (7.6)          | 1.45 (1.01-2.08) |
| 3 ml to < 4ml   | 62 | 9 (14.5)                   | 1.32 (0.65-2.68) | 5 (8.1)           | 1.55 (0.75-3.20) |
| 4 ml to < 5ml   | 28 | 2 (7.1)                    | 0.60 (0.10-3.73) | 0 (0.0)           | n/a          |
| >= 5ml          | 260| 32 (12.3)                  | 1.09 (0.72-1.64) | 14 (5.4)          | 1.01 (0.62-1.63) |

* Likelihood ratio positive for bacteriologically-positive sputum.
** CI: Confidence interval.
# Lower confidence limit is rounded up from 0.995
§ Difference in proportions, bacteriologically-positive, between Xpert MTB/RIF and smear is significant. p<0.001
1Omnibus tests for appearance (Xpert MTB/RIF and smear) not significant, p>0.05.
2Omnibus test for volume was significant (p<0.05) for Xpert MTB/RIF, but was non-significant for smear
| Characteristics         | Patients with salivary specimen | Patients with non-Salivary specimen | aOR* | 95% CI** | p value |
|-------------------------|---------------------------------|-------------------------------------|------|----------|---------|
| Age < 35                | 315 133 (42.2%)                 | 329 154 (46.8%)                    | 0.82 | 0.56-1.22 | 0.314   |
| Gender, female          | 315 183 (58.1%)                 | 329 240 (56.2%)                    | 1.08 | 0.79-1.51 | 0.649   |
| CD4 count <200          | 311 148 (47.6%)                 | 325 169 (52.0%)                    | 0.80 | 0.61-1.04 | 0.094   |
| BMI <18.5               | 313 90 (28.8%)                  | 329 81 (24.6%)                     | 1.31 | 0.83-2.01 | 0.228   |
| Hgb <10 mg/dl           | 285 60 (21.1%)                  | 278 56 (20.1%)                     | 1.04 | 0.61-1.77 | 0.893   |
| Previous TB             | 315 44 (14.0%)                  | 329 55 (16.7%)                     | 0.73 | 0.46-1.15 | 0.162   |
| Smoking***              | 315 94 (29.8%)                  | 329 105 (31.9%)                    | 0.83 | 0.55-1.27 | 0.367   |
| Alcohol use             | 315 85 (27.0%)                  | 329 85 (25.8%)                     | 1.06 | 0.73-1.36 | 0.761   |
| Miner                   | 315 22 (7.0%)                   | 329 24 (7.3%)                      | 1.01 | 0.39-2.59 | 0.981   |
| **TB Symptoms**         |                                 |                                     |      |          |         |
| Cough                   | 315 192 (61.0%)                 | 329 209 (63.5%)                    | 0.81 | 0.42-1.57 | 0.506   |
| Fever                   | 315 86 (27.3%)                  | 329 94 (28.6%)                     | 0.96 | 0.53-1.73 | 0.876   |
| Night-sweats            | 315 97 (31.0%)                  | 329 91 (27.7%)                     | 1.51 | 0.85-2.70 | 0.149   |
| Weight-loss             | 315 163 (51.8%)                 | 329 168 (51.1%)                    | 0.99 | 0.65-1.52 | 0.976   |

* AOR adjusted Odds Ratio
** CI: Confidence interval
*** Current or ex-smoker
Figure 1: patients enrolled, screened for tuberculosis symptoms and tested by Xpert MTB/RIF and smear
Figure 2: proportion of salivary sputum by study sites